Detalhe da pesquisa
1.
CAR T-cell therapy in multiple myeloma: mission accomplished?
Blood;
143(4): 305-310, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38033289
2.
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Blood;
143(8): 685-696, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37976456
3.
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Blood;
142(19): 1633-1646, 2023 11 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37390336
4.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Br J Haematol;
2024 May 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38719214
5.
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Haematologica;
2024 Apr 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38572568
6.
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Blood;
138(18): 1721-1726, 2021 11 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34115836
7.
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Haematologica;
108(4): 958-968, 2023 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36263838
8.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the ß2 and ß1 subunits of the proteasome complex.
Haematologica;
108(6): 1628-1639, 2023 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36727403
9.
All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
Haematologica;
108(2): 568-580, 2023 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36722406
10.
Gut microbiome alterations in patients with COVID-19-related coagulopathy.
Ann Hematol;
102(6): 1589-1598, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37039875
11.
Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
Br J Haematol;
198(3): 515-522, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35582835
12.
What is the future of immunotherapy in multiple myeloma?
Blood;
136(22): 2491-2497, 2020 11 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32735639
13.
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Hematol Oncol;
40(2): 202-211, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34796520
14.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol;
194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33724461
15.
Novel immunotherapies in multiple myeloma - chances and challenges.
Haematologica;
106(10): 2555-2565, 2021 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34196164
16.
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression.
Haematologica;
106(7): 1943-1956, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32354870
17.
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Ann Hematol;
100(6): 1537-1546, 2021 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33575947
18.
Management of patients with difficult-to-treat multiple myeloma.
Future Oncol;
17(16): 2089-2105, 2021 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33706558
19.
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Br J Haematol;
189(1): 67-71, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31820442
20.
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Oncologist;
25(2): 112-118, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32043788